BRIEF-Trillium Therapeutics' TTI-621 Receives Orphan Drug Designation For Treatment Of Cutaneous T-Cell Lymphoma

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.